Company news
Transcenta Holding Limited (HKEX:6628) news
Transcenta Holding Limited news releases on 6ix. Latest, Sep 30, 2026: CANCELLATION AND GRANT OF AWARD PURSUANT TO THE SHARE INCENTIVE SCHEME
Press releases & updates
CANCELLATION AND GRANT OF AWARD PURSUANT TO THE SHARE INCENTIVE SCHEME
September 30, 2026
Transcenta Therapeutics Presents New Data for its Novel LIV1-Targeting ADC TST013 Demonstrating Potent Anti-Tumor Activity in PDX Models of Prostate Cancer and ER Positive /HER2 Negative Breast Cancer
April 23, 2026
Transcenta Therapeutics Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform
March 30, 2026
Transcenta Therapeutics to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference
February 24, 2026
Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics
December 27, 2025
Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia
December 3, 2025
Transcenta Holding Limited (6628.HK) to Hold 2023 ASCO Business Update call Conference.
June 2, 2023
Transcenta Holding Limited (6628.HK) to Hold 2022 Annual Results Release Conference Call
March 20, 2023
Transcenta to Hold 3 Exchange Sessions on Post-SITC Business Update Call & TST003 data release and pipeline development progress update
November 9, 2022
Transcenta to Present Two Scientific Posters at SITC 2022 Annual Meeting
October 12, 2022